Bariatric surgery in AT
Bariatric surgery in AT section, includes general infrmation about Bariatric surgery Procedure, Bariatric surgery AT Local News, Bariatric surgery AT Surgeon Locator and other Bariatric surgery related material.
Bariatric surgery Procedure
Bariatrics is the branch of medicine that deals with the causes, prevention, and treatment of obesity.
The term “bariatrics” refers to "weight medicine". Bariatrics generally deals with pharmacotherapy of obesity and with obesity surgery.
Overweight and obesity are strongly related to medical problems in today’s world. There are many health effects of obesity, such as heart disease, diabetes, many types of cancer, asthma, obstructive sleep apnea, chronic musculoskeletal problems, and others.
In addition to medical concerns regarding obesity, appearance (look) has a major relevance to weight and obesity.
Although diet, exercise, behavior therapy and anti-obesity drugs are first-line treatment, medical therapy for severe obesity has limited short-term success and almost nonexistent long-term success. Therefore, obesity surgery (or bariatric surgery) has been a popular treatment in the war against obesity. Weight loss surgery generally results in greater weight loss than conventional treatment, and leads to improvements in quality of life and obesity related diseases such as hypertension and diabetes.
Before someone can become a candidate for bariatric surgery, certain criteria must be met. The basic criteria are:
[1] An understanding of the operation and the lifestyle changes the patient will need to make;
[2] A body mass index (BMI) of 40 or more, which is about 45 kg (100 pounds) overweight for men and 35 kg (80 pounds) for women; or
[3] A BMI between 35 and 39.9 and a serious obesity-related health problem such as type 2 diabetes, heart disease, or severe sleep apnea (when breathing stops for short periods during sleep).
Risks involved
Past studies found that 10 to 20 percent of bariatric surgery patients had complications while they were in the hospital. In 2006, federal researchers found that 39.6 percent of patients had complications within 180 days of surgery. The most common complications are:
[1] A composite of gastrointestinal symptoms including vomiting, diarrhea, dysphagia, and reflux (20%)
[2] Anastomotic leaking (at the surgical connections between the stomach and the intestine) (12%);
[3] Abdominal hernia (7%)
[4] Infections (6%).
About 7% of patients were re-admitted to the hospital within 6 months to treat complications specific to the bariatric procedure.
The in-hospital death rate in adults undergoing obesity surgery in 2003 was 0.2%.
Laparoscopic surgery has become an important addition to this field of surgery, and demand soars, amidst scientific and ethical questions.
Surgical procedures in bariatrics
There are a number of surgical options available to treat obesity, each with their advantages and pitfalls. In general, weight reduction can be accomplished, but one must consider operative risk (including mortality) and side effects. Usually, these procedures can be carried out safely.
The surgical procedures can be grouped in three main categories:
[1] Predominantly malabsorptive procedures: although also reducing stomach size, these operations are based mainly on diversion and bypass.
[2] Predominantly restrictive procedures: a surgery that primarily reduces stomach size: Vertical Banded Gastroplasty (Mason procedure, stomach stapling); Adjustable gastric band (or "Lap Band"); Sleeve gastrectomy.
[3] Mixed procedures: applying both techniques simultaneously: gastric bypass surgery, like Roux-en-Y gastric bypass; Sleeve gastrectomy with Duodenal Switch Implantable Gastric Stimulation.
Biliopancreatic diversion
A complex operation, also known as biliopancreatic diversion (BPD), or Scopinaro procedure.
This surgery is rare now because of problems with malnourishment. It has been replaced with the Duodenal Switch, also known as the BPD/DS. Part of the stomach is re-sected, creating a smaller stomach (however after a few months the patient can eat a completely free diet as there is no restrictive component). The distal part of the small intestine is then connected to the pouch, bypassing the duodenum and jejunum. This results in around 2% of patients severe malabsorption and nutritional deficiency that requires restoration on the normal absorption.
The malabsorptive element of BPD is so potent that those who undergo the procedure must take vitamin and mineral supplements above and beyond that of the normal population. Those that do not run the risk of deficiency diseases such as anemia and osteoporosis.
Because gallstones are a common complication of rapid weight loss following any type of weight loss surgery, some surgeons may remove the gall bladder as a preventative measure during BPD. Others prefer to prescribe medication to reduce the risk of post-operative gallstones.
Far fewer surgeons perform BPD compared to other weight loss surgeries, in part because of the need for long-term nutritional follow-up and monitoring of BPD patients.
Vertical Banded Gastroplasty
a part of the stomach is permanently stapled to create a smaller pre-stomach pouch, which serves as the new stomach.
The same effect can be created using a silicone band, which can be adjusted by addition or removal of saline through a port placed just under the skin. This operation can be performed laparoscopically, and is commonly referred to as a "lap band."
Adjustable Gastric Banding
The first lower pressure, wider, one-piece adjustable gastric band called the MIDband® was introduced in 2000. Unlike many of the early bands this was designed specifically for laparoscopic insertion.
Other Bariatric surgery Procedures:
All Body Procedures Procedures
Bariatric surgery AT (current)
AT Buttock Augmentation
AT Calf Augmentation
AT Liposuction
AT Body Contouring
More AT info...
Austria Regions Map of AustriaAustria is a federal state comprised of nine states:
Burgenland
Carinthia (K?rnten)
Lower Austria (Nieder?sterreich)
Salzburg
Styria (Steiermark)
Tyrol (Tirol)
Upper Austria (Ober?sterreich)
Vienna (Wien)
Vorarlberg
Austria History Once the center of power for the large Austro-Hungarian Empire, Austria was reduced to a small republic after its defeat in World War I. Following annexation by Nazi Germany in 1938 and subsequent occupation by the victorious Allies in 1945, Austria's status remained unclear for a decade. A State Treaty signed in 1955 ended the occupation, recognized Austria's independence, and forbade unification with Germany. A constitutional law of that same year declared the country's "perpetual neutrality" as a condition for Soviet military withdrawal. This neutrality, once ingrained as part of the Austrian cultural identity, has been called into question since the Soviet collapse of 1991 and Austria's entry into the European Union in 1995. A prosperous country, Austria entered the European Monetary Union in 1999.
Plastic Surgery News...
- NICE has issued a Final Appraisal Determination (FAD) on coronary artery stents for ischaemic heart disease. The appeal period for this appraisal will close on 15 February 2008.
The preliminary recommendations are that drug-eluting stents (DES) are recommended for use in percutaneous coronary intervention for the treatment of coronary artery disease, within their instructions for use, only if the target artery to be treated has less than a 3mm calibre or the lesion is longer than 15mm, and the price difference between DES and bare-metal stents is no more than £300.
The FAD notes that following data published in 2006, the FDA’s Circulatory Devices Systems Advisory Panel had recommended that the duration of clopidogrel use should be extended in patients receiving a DES. In addition, the American College of Cardiologists/American Heart Association PCI guidelines (also endorsed by the Society for Cardiovascular Angiography Interventions and the British Cardiovascular Intervention Society) have recommended that for patients receiving DES, the duration of clopidogrel use should be increased to at least 12 months, after which time continuation of clopidogrel should be reviewed taking into account the risk for further events on an individual patient basis.
- In a BMJ editorial, the authors from Imperial College write that despite evidence for the effectiveness of multitargeting kinase inhibitors in treating renal cell cancer, their availability in the UK has lagged behind that in the US because of the time taken to obtain regulatory approval. They note that renal cell cancer is a relatively unusual tumour that is diagnosed in about 2500 people each year in the UK and accounts for less than 1% of deaths from malignant disease. The evidence for bevacizumab, lapatinib, temsirolimus, sunitininb and sorafenib are then reviewed, along with a discussion about the possibility of combining these agents and using them with cytokines. They conclude “potentially there is real hope for patients with kidney cancer, but when will hope translate into the reality of treatment being available in the UK?” They point out that sunitinib was approved by the FDA in January 2007, in the same month that the trials were published; sunitinib and sorafenib were licensed by the European Medicines Agency in July 2006. They argue that patients in the UK should not have to wait another two years until NICE approves use of such treatments.